News & Updates
Filter by Specialty:
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
02 Nov 2021
byAudrey Abella
In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
02 Nov 2021Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021
byRoshini Claire Anthony
Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021
Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.